Quetiapine monotherapy for bipolar depression

por Thase, Michael E
Publicado 2008

Depression and sleep: pathophysiology and treatment

por Thase, Michael E.
Publicado 2006

Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies

por Thase, Michael E.
Publicado 2014

A Review of Vilazodone, Serotonin, and Major Depressive Disorder

por Pierz, Kerri A., Thase, Michael E.
Publicado 2014

Treatment resistance in psychiatry: state of the art and new directions

por Howes, Oliver D., Thase, Michael E., Pillinger, Toby
Publicado 2021

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder

por Thase, Michael E., Chen, Dalei, Edwards, John, Ruth, Adam
Publicado 2014

Comparative Assessment of Adherence Measures and Resource Use in SSRI/SNRI-Treated Patients with Depression Using Second-Generation Antipsychotics or L-Methylfolate as Adjunctive T...

por Wade, Rolin L., Kindermann, Sylvia L., Hou, Qingjiang, Thase, Michael E.
Publicado 2014

Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder

por Brunner, Elizabeth, Tohen, Mauricio, Osuntokun, Olawale, Landry, John, Thase, Michael E
Publicado 2014

Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder

por Thase, Michael E., Gommoll, Carl, Chen, Changzheng, Kramer, Kenneth, Sambunaris, Angelo
Publicado 2016

Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double‐blind, placebo‐controlled study

por Durgam, Suresh, Chen, Changzheng, Migliore, Raffaele, Prakash, Chandran, Thase, Michael E.
Publicado 2019

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies

por Thase, Michael E, Weiller, Emmanuelle, Zhang, Peter, Weiss, Catherine, McIntyre, Roger S
Publicado 2018

Does Symptom Linkage Density Predict Outcomes in Cognitive Therapy for Recurrent Depression?

por Vittengl, Jeffrey R., Clark, Lee Anna, Thase, Michael E., Jarrett, Robin B.
Publicado 2022

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

por Ball, Susan G, Desaiah, Durisala, Zhang, Qi, Thase, Michael E, Perahia, David G S
Publicado 2013

PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies

por Eriksson, Hans, Weiller, Emmanuelle, Weiss, Catherine, Zhang, Peter, Skuban, Aleksandar, Thase, Michael E.
Publicado 2016

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

por Gommoll, Carl, Durgam, Suresh, Mathews, Maju, Forero, Giovanna, Nunez, Rene, Tang, Xiongwen, Thase, Michael E
Publicado 2015

Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches

por Batievsky, Daniella, Weiner, Michelle, Kaplan, Shari B., Thase, Michael Edward, Maglione, Domenick Nicholas, Vidot, Denise Christina
Publicado 2023

Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder

por McIntyre, Roger S., Gorwood, Philip, Thase, Michael E., Liss, Charlie, Desai, Dhaval, Chen, Ji, Bauer, Michael
Publicado 2015

Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)

por Keyloun, Katelyn R., Hansen, Ryan N., Hepp, Zsolt, Gillard, Patrick, Thase, Michael E., Devine, Emily Beth
Publicado 2017

Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial

por Durgam, Suresh, Gommoll, Carl, Migliore, Raffaele, Chen, Changzheng, Chang, Cheng-Tao, Aguirre, Michelle, Thase, Michael E.
Publicado 2018

OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females

por Brin, Mitchell F., Durgam, Suresh, Lum, Arlene, James, Lynn, Liu, Jeen, Thase, Michael E., Szegedi, Armin
Publicado 2020